|
PET Scan of Brain Metabolism in Relation to Age and Disease Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on PET Scan of Brain Metabolism in Relation to Age and Disease conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. PET Scan of Brain Metabolism in Relation to Age and Disease Clinical research trials and PET Scan of Brain Metabolism in Relation to Age and Disease medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including PET Scan of Brain Metabolism in Relation to Age and Disease. PET Scan of Brain Metabolism in Relation to Age and Disease Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a PET Scan of Brain Metabolism in Relation to Age and Disease clinical trial. Participants oftentimes recieve the finest healthcare available for their PET Scan of Brain Metabolism in Relation to Age and Disease condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > PET Scan of Brain Metabolism in Relation to Age and Disease  PET Scan of Brain Metabolism in Relation to Age and Disease
PET Scan of Brain Metabolism in Relation to Age and Disease
For Condition: Alzheimer's Disease,Brain Neoplasm,Niemann Pick Disease
Status: Completed
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: The main source of energy for the brain comes from a combination of oxygen and glucose (sugar). For brain cells to function normally they must receive a constant supply of these nutrients. As areas of the brain become more active blood flow into and out of these areas increase. In addition to oxygen and glucose, the brain uses chemical compounds known as phospholipids. These phospholipids make up the covering of nerve cells that assist in the transfer of information from cell to cell. Without phospholipids brain cell activity may become abnormal and cause problems in the nervous system. Certain diseases like Alzheimer's disease and brain tumors can affect blood flow to the brain and change the way the brain metabolizes phospholipids. In addition to diseases, changes in the brain occur with normal healthy aging. This study is designed to use PET scan to measure changes in blood flow and changes in phospholipid metabolism. Using this technique, researchers can improve their understanding of how certain diseases change the shape and function of the brain.
Details: The Brain Physiology and Metabolism Section (BPMS) of the National Institute on Aging (NIA) and the Clinical Neuroscience Program (CNP) of the National Institute of Neurological Disorders and Stroke (NINDS) propose to study regional brain phospholipid metabolism in young and old normal volunteers and in patients with Alzheimer disease. The method to be employed, developed from animal studies, involves the intravenous injection of a radiolabeled polyunsaturated fatty acid, [11C]arachidonic acid and measuring regional brain radioactivity using positron emission tomography (PET). A mathematical model is used to calculate regional brain incorporation coefficients k* of [11C]arachidonate into brain. These reflect brain signal transduction and membrane turnover involving phospholipids and the signal transduction and membrane turnover involving phospholipids and the activation of the enzyme, phospholipase A2. PET also will be used in the same subjects to measure regional cerebral blood flow (rCBF), a marker of brain energy metabolism, with radioactive water ([150]H20). The literature reports that rCBF and energy metabolism decline with age and are markedly reduced in Alzheimer disease. We hypothesize that (a) we will be able to quantify and image incorporation of [11C]arachidonate into the human brain for the first time, (b) in normal volunteers, k* for arachidonate will be correlated on a regional basis with rCBF, (c) rCBF will be reduced in the older compared with the younger normal volunteers, and markedly reduced in Alzheimer disease patients compared with the older volunteers (controls), (d) the normal coupling (regression) relation between k* and rCBF will be disturbed in Alzheimer disease. This protocol originally proposed to measure brain incorporation of two labeled fatty acids, [11C]arachidonate and [11C]palmitate, as well as rCBF, in young and old normal volunteers, and in patients with Alzheimer disease, Niemann-Pick Type C disease and brain tumors. Eleven patients with Alzheimer disease have been scanned using [11C]arachidonate and [150]H20, compared with 10 volunteers. The current amendment proposes to use only [11C]arachidonate and [150]H20 in 16 additional normal volunteers, and to compare the results between old and young groups and patients with Alzheimer disease. A request to study only 16 additional normal volunteers was approved by the NINDS IRB at the Continuing Review in 1999, and has not changed since then.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: NORMAL VOLUNTEERS: Age between 18 and 90 years. No past or current medical condition that would interfere with brain function. No history of alcoholism, psychiatric or neurological illness, head trauma with loss of consciousness, history of exposure to central nervous system toxin; history of central nervous system infection, metabolic, endocrine, connective tissue disease; hypertension or other cardiovascular disorder; abnormal renal, liver or pulmonary function; blood or coagulation disease; malignancy; psychopharmacological treatment; neurodegenerative or neurodevelopmental disorder; stroke; epilepsy; subjects requiring regular medication, and subjects demonstrated by drug screening to have taken a controlled substance. No occupational exposure to metal slivers or shavings. No females who are pregnant or breast feeding. PATIENTS WITH ALZHEIMER DISEASE: Age between 18 and 90 years. Diagnosis of possible or probably Alzheimer Disease according to NINCDS-ADRDA criteria. Aside from Alzheimer Disease, no past or current medical condition that would interfere with brain function. No history of alcoholism, psychiatric or neurological illness, head trauma with loss of consciousness, history of exposure to central nervous system toxin; history of central nervous system infection, metabolic, endocrine, connective tissue diseases; hypertension or other cardiovascular disorder; abnormal renal, liver or pulmonary function; blood or coagulation disease; malignancy; psychopharmacological treatment. No females who are pregnant or breast feeding.
Total Enrollment: 123
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 940205; 94-N-0205
Study Start Date: September 14, 1994
Record last reviewed: August 1, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001972
Other Niemann Pick Disease Studies:
1. Effects on sleep and attention of two currently marketed drugs for Alzheimer's disease
2. Brain Study of Patients with Frontal Lobe Dementia and Parkinsonian Disorders
3. Safety testing of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Laughter & Crying)
4. High Intensity Light Therapy in Alzheimer's Disease
5. Diagnosis and Natural History Study of Patients with Neurological Conditions
Related Studies:
Other Niemann Pick Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
PET Scan of Brain Metabolism in Relation to Age and Disease
|
|
|
|
|
|
|
|
